A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer

Abstract

Cis and Carb have similar efficacy, tolerability, and effect on QOL and both can be used as a first-line treatment of squamous NSCLC.

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis

“…Of these, 12 RCTs were included, which involved a total of 4,139 patients ( Fig. 1) [14][15][16][17][18][19][20][21][22][23][24][25]. Relative to the previous Cochrane meta-analysis upon which the current review was based, two new RCTs were added, and updated results were captured from a third RCT [24][25][26].…”

“…1) [14][15][16][17][18][19][20][21][22][23][24][25]. Relative to the previous Cochrane meta-analysis upon which the current review was based, two new RCTs were added, and updated results were captured from a third RCT [24][25][26]. Of the included RCTs, the platinum agents were combined with: gemcitabine (n = 5) [14,18,23,24,26], paclitaxel (n = 5) [15,[19][20][21][22], docetaxel (n = 1) [17], or pemetrexed (n = 1) [25].…”

“…One RCT was conducted in an elderly population, with nearly half of patients having performance status (PS) 2 [15]. One RCT was restricted to squamous NSCLC patients [24]; other RCTs included patients with either squamous (17%-56% of patients) or non-squamous histology [20,21].…”

“…Cisplatin was typically administered on day 1 at 60-80 mg/m 2 ; one RCT included a dose of 100 mg/m 2 on day one [22], and two RCTs [14,24] used a dosing schedule of 30-40 mg/m 2 on days one and three (Appendix A, Table A.2). Additionally, Ferry et al (2017) examined cisplatin dosing of 50 mg/m 2 against a dosing of 80 mg/m 2 , both administered on day one [26].…”

“…Ten of the 12 RCTs expressed OS as a HR [15,[17][18][19][20][21][23][24][25][26]. The overall pooled estimate for carboplatin relative to cisplatin suggested no significant difference in the risk of death (HR = 1.08; 95% confidence interval [CI]: 0.96,1.21; I 2 = 49%) ( Fig.…”